Article Text
DTB select
EMA suspends licence for ingenol mebutate (Picato)
Abstract
Every month, DTB scans sources of information on treatments, disease management and other healthcare topics for key items to bring to our readers’ attention and help them keep up to date. To do this, we produce succinct, contextualised summaries of the information concerned.
- adherence
- adverse effects
Statistics from Altmetric.com
Footnotes
Overview of: Medicines and Healthcare products Regulatory Agency. Ingenol mebutate gel (Picato▼): suspension of the licence due to risk of skin malignancy. Drug Safety Update 2020;13(7):1.
Contributors DTB Team.
Provenance and peer review Commissioned; internally peer reviewed.